Donanemab promises progress. The FDA shouldn’t hold out for perfection. A Food and Drug Administration committee meets June 10 to issue a recommendation for donanemab, a drug to treat Alzheimer’s disease. As a practicing geriatrician, I often get questions from patients about whether it or other drugs will cure the disease. The answer is that while there’s no silver bullet, it is a leap in the right direction.
Howard Fillit
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Howard
Contact Howard, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack